PT  - JOURNAL ARTICLE
AU  - Andrew W Bergen
AU  - James W Baurley
AU  - Carolyn M Ervin
AU  - Christopher S McMahan
AU  - Joe Bible
AU  - Randall S Stafford
AU  - Seshadri C Mudumbai
AU  - Andrew J Saxon
TI  - Buprenorphine treatment of opioid dependence: analysis of individual patient data
AID  - 10.1101/2020.03.18.20038430
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20038430
4099  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038430.short
4100  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038430.full
AB  - Background The efficacy and safety of buprenorphine alone and in combination with naloxone for treatment of opioid dependence were evaluated in Federally-sponsored randomized clinical trials. Meta-analysis of pooled individual participant data provides an opportunity to identify multiple predictors of buprenorphine treatment outcome.Methods We selected six buprenorphine efficacy and safety trials from NIDA’s Data Share database for analysis. Treatment, sociodemographic, and drug use history variable domains were systematically harmonized and included in analysis. After exclusions, 3,022 participants randomized or enrolled in buprenorphine treatment for opioid dependence (mean (SD) age 36.1 (9.8) years, 33% female, 66% White, 16% Hispanic, 14% Black), were analyzed using a generalized linear mixed model with time-weighted treatment variables and participant covariates. We defined positive urinalysis or self-reported lapse as the primary outcome.Results Four treatment variables were significantly associated (p < 0.001) with lapse. Time-weighted dose and time-weighted adaptive dose had greater estimated effects than time-in-trial and time-weighted clinic visit. All treatment variables were novel predictors of lapse.Conclusions In a large cohort of trial participants treated with buprenorphine and behavioral counseling for opioid dependence, we identified and ranked four novel treatment factors reflecting components of buprenorphine dose, clinical provider engagement and patient engagement. Additional research to explore the effects of pharmacologic and non- pharmacologic treatment factors, and to explore relations with provider and patient factors will help our understanding of buprenorphine treatment outcomes. Continued analyses of publicly available data will extend discovery and support development of personalized opioid use disorder treatments.Highlights (3 to 5 bullet point max 85 characters each including spaces)Treatment and participant variables were harmonized in six buprenorphine trialsTime-weighted treatment variables were used in a random effects mixed model of lapseBuprenorphine dose and three clinical interactions were protective against lapseSupport of protective treatment factors may improve buprenorphine treatment successCompeting Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: AWB, JWB, CME and CSM report grants from NIDA (R43 DA046325) and from NIAAA (R44 AA027675), NIH, during the conduct of the study; in addition, AWB, JWB, CME and CSM have a patent 62/986,173 pending to BioRealm, LLC; in addition, JWB reports personal fees from BioRealm LLC, outside the submitted work; in addition, AJS reports Dr. Saxon reports personal fees and other from Alkermes, Inc., grants from Medicasafe, Inc., personal fees from UpToDate, Inc., outside the submitted work; and, JB, RSS and SCM have nothing to disclose.Funding StatementDrs. Bergen, Baurley, Ervin, and McMahan were supported by National Institute on Drug Abuse grant R43 DA046325 and National Institute on Alcohol Abuse and Alcoholism grant R44 AA027675. Dr. Mudumbai's research is supported by Food Drug Administration PMR Study 3033-1A (Syneos Corp.) and VA HSRD Merit Grant I01 HX002314-01A1. Dr. Saxon is supported by the Center of Excellence in Substance Addiction Treatment and Education at VA Puget Sound Health Care System.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical trial data are available from NIDA's Division of Therapeutics and Medication Consequences (DTMC) and the Clinical Trials Network (CTN) at NIDA's Data Share database (datashare.nida.nih.gov). https://datashare.nida.nih.gov/